Endoscopy Unplugged by ESGE

Transcript

Back to episode

Mario Dinis Ribeiro: Mario Dinis Ribeiro We are moving away from random biopsies to target biopsies and we are moving away from only trusting pathologists to trust also eyes and then to determine the risks.

Opening jingle: Opening jingle Welcome to the ESGE podcast, Endoscopy Unplugged. Join us each month to hear the latest from European experts and where we'll discuss relevant clinical topics and provide you with tips and tricks, practical scientific evidence and pearls of wisdom to inform your endoscopy practice. So please subscribe wherever you get your podcasts and join us as we advance GI endoscopy care.

Ian Gralneck: Ian Gralneck Hello, everyone, and welcome to episode 10 of ESGE's podcast, Endoscopy Unplugged. My name is Ian Gralneck, past president of the ESGE, and I'm your host. Today's podcast is titled Catching Gastric Cancer Early: Endoscopic Screening and Management of Precancerous Conditions and Neoplasia. And I'm very happy to say my guest today is Professor Mario Dinis- Ribeiro, who is chair of the Department of Medicine at the Porto Comprehensive Cancer Center and professor at the Porto Faculty of Medicine in Porto, Portugal. Mario, of course, everybody knows, is a past president of the ESGE, and he is currently the Secretary General of the World Endoscopy Organization. Mario is the lead author of one of the most important ESGE publications in the last few years: the Management of Epithelial Precancerous Conditions and Early Neoplasia of the Stomach Guideline. That was updated in 2025. This is commonly referred to as the MAPS III guideline. Welcome, Mario, to the podcast.

Mario Dinis Ribeiro: Mario Dinis Ribeiro Thank you, Ian, and thank you, for everything that ESGE does for us, the community of endoscopists and also for inviting me for this podcast.

Ian: Ian It's great to have you here. Before we get into the details of all this, I just I wanted to ask you, how did you decide to pursue a career in in endoscopy?

Mario Dinis Ribeiro: Mario Dinis Ribeiro After I made an option for for becoming a medical doctor, there was a few fields that I became interested and GI diseases was the excuse to get into gastroenterology and and in Portugal the training comes along. Also when I when I decided to to visit some centres to make it my my programme I saw something I I didn't see during my training programme I saw a polyp being removed, a two centimetres polyp. So I was just finishing my basic training. By then the the endoscopy was not, I think, taught as now nowadays it's taught in the in in the pre graduate school and it was something that I said, Well, I want to do this.

Ian: Ian Okay, cool. Well we're we're glad you made yeah, we're we're glad

Mario Dinis Ribeiro: Mario Dinis Ribeiro I want to remove polyps, huh?

Ian: Ian you made that choice. all right, so let let's get at it right now. Can you can you really walk our listeners through the pathway of atrophic gastritis to intestinal metaplasia to dysplasia to early gastric cancer? Where does the risk really start climbing for for the patient?

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah, that's interesting. I think that concept of risks and baseline risks and ultimately lifetime risks is is of paramount important to define everything else. And yeah, we we do know the so-called perfect Correa cascade that it's it's as of course a model that starts by saying that from a normal stomach gastritis occurs and then some individuals will develop folci of atrophic changes and and intestine metaplasia, and finally cancer. This seems to be a let's say a sequence. Of course, it's it is a sequence, but I think we need to introduce a layer of complexity here these changes are multifocal and of paramount importance is the extension that these changes, let's say, occur in the stomach. So if if if you do have a trophic changes and intestinal metaplasia occurring in different places in the stomach, namely from the antrum and involving the corpus, then the risk starts increasing. And it moves from, for instance, if you do use as a baseline risk individuals with nothing or trophic changes, or even minimal changes of intestinal metaplasia, the risk is 0.2, 0.3%. You may compare this with parts, for instance, for dysplasia, but if it is extensive then the risk goes over one percent every year of having a metaplasia found during surveillance.

Ian: Ian Okay. So let's say you know you're doing a gastroscopy for somebody who's having dyspepsia or GERD like symptoms and you take a random gastric biopsy, let's say from the antrim, and and you and you found when you get your pathology back that there's intestinal metaplasia. What do you do next? what's your plan for this patient at that point?

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah, that's interesting. so this is of course a a question that in my current practice, I of course I try as much as possible. And this is something that we as a community should also teach slash make it mandatory when we receive the reports, is that I try it first to assess if the quality of endoscopy was described, slash if I'm doing the best endoscopy I can. So if I clean the mucosa or if I if I didn't miss anything. So if the only problem is intestine metaplasia, sort of. And then for

Ian: Ian Mm-hmm.

Mario Dinis Ribeiro: Mario Dinis Ribeiro instance, if you if you receive a report with one single biopsy referring to intestine metaplasia, the question is, okay, where did it come? Because if it is one sample, maybe the endoscopist thought it was normal, then it did yes, random biopsies, but it puts everything in the same jar. So the message I would say it's just first assess the quality of what of of what you are doing. And then if I do receive those reports with one single endoscopy, I'd say to the patient, Yeah, we don't know, huh? We don't know if this is just one spot or if you have extensive. Sometimes depending on the values of the patients, of course, I say, Yeah, let's think that if you have if you would have extensive intestinal metaplasia and Yeah, at the baseline the quality of endoscopy was nice, then I would follow this patient in three years. If I have serious doubts because the patient can continues with complaints, is not very safe about the previous endoscopy, then I may repeat endoscopy with proper staging, staging of intestine metaplasia. And maybe we can discuss this further.

Ian: Ian So so that's interesting. I mean, because this happens. I mean, I get these types of reports back all the time. And I always think, okay, what do I do now? So if I understand you correctly, if you think the quality of endoscopy was good, there was no suspicion at the time of that original gastroscopy, and there's no other potential risk factors, you would actually wait three years to repeat the upper endoscopy? Is that what I'm hearing?

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah, yeah, you you could even wait more, but it's it's a kind of contradictory thing that I'm saying, because if the endoscopy's that did endoscopy just did one vial, I guess that the quality was not that good. But it happens because of many reasons. So for instance let's the do the other way around. So the endoscopy was good. Endoscopist did the mapping but by any chance, I don't know the the the pathology merge everything in one vial. So it happens also in real life. And then you and then you receive one spot with intestine metaplasia. So I don't think we should transmit too much risk to this patient because probably the risk is too small. On the other side, you don't know, and and eventually, yeah. So I what I say to the patient come in 1000 days. So I I try to transmit that the risk is probably too low. But to you need to be sure and it will depend. So if you follow the guidelines. If you have a perfect endoscopy, if you Ian did the perfect endoscopy and you did the the the two compartments assessment, then one single spot of complete intestine metaplasia is to probably to in the future to release the patient from surveillance. But according to the guidelines, you don't need to surveil this patient. So this is also a message that is it's important in the guidelines, is that the majority of patients will not deserve surveillance.

Ian: Ian okay. So maybe I I didn't I guess extend my question in the right way because so you're saying after gastric mapping, okay, which I'm gonna get to in a second. But I'm saying what if I just took a biopsy in the antrum because I was worried about H. pylori or something and it was one bottle and that comes back with intestinal metaplasia, then do you automatically reschedule that patient to come back to do formal gastric mapping? I guess that's my question.

Mario Dinis Ribeiro: Mario Dinis Ribeiro I I think I think we should, because for instance, if you were concerned about H. pylori and even if you don't believe in in what we are saying, there is, consistency saying that you need to map the stomach. So if that endoscopist just did one endoscopy, it's probably it it's a reflection and according to the quality parameters that the ESGE recently developed. To do staging, it's one of the principal key performance measures. So it I don't think we can say that high-quality endoscopy was done if only one biopsy was done. There may be reasons for that. So if for instance if if the if the endoscopy is suspected of a lesion, then this is this is even more troublesome. So in in current practice, I I think we should probably consider this endoscopy with one single biopsy done in the antrum, not a proper endoscopy.

Ian: Ian Okay, no, I agree. But at that point, if you found intestinal metaplasia, you're gonna schedule that patient to come back and do formal mapping of the stomach to make sure there's not multifocal intestinal metaplasia, correct? Okay.

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah, yeah, yeah. Yeah. And and and most of all, if if there was no missing cancers, because if it is a a low quality endoscopy, this probably may preclude any diagnosis that is even more important.

Ian: Ian I yeah, exactly. Okay, so all right, so so now let's take another the next step. So what's your biopsy protocol when you bring that patient back to do gastric mapping? Explain to me how you do that.

Mario Dinis Ribeiro: Mario Dinis Ribeiro So you need to understand that there are two major compartments, the antrum and the corpus, and they are affected differently. In principle, if the model occurs as we expect, you will have changes in the antrum first and then it goes up to the corpus, this following the H pylori cascade and I don't want to get into other let's say causes of atrophic like like auto immune because of course the it's reverse. But in any case, the compartment should be addressed separately. Of course, you do it properly by endoscopy. And then if you if you are not trained or if you are not adequately aware of which kind of fixtures you should look in the mucosa, you should try to do the mapping in the antrum with two biopsies in the lesser curvature and the greater curvature. It's important to do it away from the pyloris because it's almost ubiquitous changes in the pre in the in the peripyloric area so you should avoid to do biopsies two to three centimetres next to the pyloris because in most cases you would upgrade this patient to something that is not there yet so if you don't use advanced or chromendoscopy and if you are not aware of those fixtures just do these two biopsies place it in the jar and then you make two other in the corpus yeah yeah and we consider that the biopsy in the incisura was kind of the number needed to make a biopsy in the cesura to make one difference one patient differently managed was too high to to make it mandatory. So if if you are used to make a three biopsies, two in the Andromeda and one in the cesura, then you place these three in one jar and then you place the other two in the corpus, in a different jar and you ask the the the pathology to report this separately.

Ian: Ian So you're ultimately sending two bottles or three bottles?

Mario Dinis Ribeiro: Mario Dinis Ribeiro Two bottles, two bottles.

Ian: Ian Okay. So you're putting all the antral biopsies in one bottle and you're putting the corpus biopsies in one bottle and you're sending that to Okay. So then when when you send that to pathology, are you expecting them to come back with you with like a olgum score or something like that? Is that your expectation? Cause I cause I because I don't get that. I don't get that routinely from pathology.

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah. this is something that that was one of the reasons also to to go for the map three because we understood from a systematic review and also from from auditing and reports that the use of scores, we are all fan of scores, but it's not there in in most of the let's say the settings that we work with. But it in in my practice I I mostly look at OLGIM and EGGIM, meaning because intestine metaplasia it's not only the ultimate marker of risk, but it's more reliable. Of course, it can happen that you you may have an atrophic stomach with atrophic changes without intestinal metaplasia, and this also it harbours risk. However, the interobserver reliability for pathologist and also our intra and intra observer reliability for atrophic is not that good as it is for decimetaplasia. At least conventionally we say this because we need probably to come back with the new methods of white light for by some providers that are so good that probably we may get there. But in 2026 I think we should convey to our community that you should first of all discuss with your pathologists what you need.

Ian: Ian Okay.

Mario Dinis Ribeiro: Mario Dinis Ribeiro And if they do follow their guidelines, their own guidelines, they sh they need to report all the fixtures that will lead to the classification. So you may not have the OLGA and OLGIM in your report, but you may have the severity of atrophy and the severity of intestinal metaplasia in those vials that you had, and then you you may sum up. And a good proxy is is that if you do have severity in the antrum, you may guesstimate that you will have some sort of advanced stages, but of course if you have intestinal metaplasia in both compartments, you you have a proxy of extensive intestinal metaplasia, meaning that this patient deserves surveillance.

Ian: Ian So so in a in a perfect world, we should be trying to have a discussion with our pathologist saying that we'd really appreciate them providing us with an OLGIM score. Okay. No, I think I think that's really important because I like I said, I don't routinely get those types of scores and I'm not always so sure they even provide whether it's mild or severe.

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah. But if if they if they do come back, that it's difficult, it's truly difficult. So you may say, Okay, at least report me the severity and and if there is intestinal metaplasia or not, because then it's more reliable and probably there is not such a difference in the number of patients that you will miss or you allocate wrongly to surveillance. But one important thing is out it's also that we as a community. And this is something we try to reflect and that's probably why we have so many scores in these MAPS III guidelines is that if you confront the East to the West practice, there is not such a thing of multiple biopsies in in the stomach in the East, because most of the Eastern endoscopists are trained to trust their own eyes and look at the stomach as an entire organ. So, for instance, one of the things that is also important is that when you do one biopsy and the report comes with extensive intestinal metaplasia for that small piece, and you need to, let's say, convey this to the patient because sometimes they come with fear that I have extensive metaplasia and I I went to the website of ESGE and I saw this this is a mark of risk. But you need to explain that this is this is was in one single biopsy. So this cross talk with patients and with the community and with with pathology deserves quite a lot of work during the next years.

Ian: Ian Okay. I think that that that was very, very helpful. What what about a patient who you find low grade dysplasia?

Mario Dinis Ribeiro: Mario Dinis Ribeiro yeah, that's that's very important. I will not get into the discussion of which kind of dysplasias you may have in the stomach, but to be let's say basic, you need to interpret as a significant marker of risk. So the first question again is was the quality, of the baseline endoscopy good. So it was this a random biopsy that ultimately revealed low grade dysplasia. Was the low grade dysplasia reported by two pathologists? so all of these things should be, let's say, again, comprehensively considered. Let's let's take an example. So you did you you received a report with with no description of the cleaning, and then one biopsy was done and suddenly low grade dysplasia came. So this is a patient to surveil slash repeat endoscopy endoscopy in a short time. On the other side it was a high quality endoscopy, nothing was seen and by surprise two pathologists reports the presence of low-grade dysplasia. This can happen, and according to guidelines, you may surveil this you should eradicate H. bylori, and then you should make this patient come in six to twelve months. It's probably 12 months, this is probably enough because most of these things, in even for post endoscopy cancers, we do know that these processes are slow. it can happen that if you repeat that so-called low quality endoscopy that we discussed before, or even during this surveillance, you see it a lesion. Yeah. So because then you have a an a priori obligation to don't miss anything. And sometimes it happens that you go back to the stomach and the lesion was there. It was considered a a normal mucosa, it was overlooked as a lesion. Then you clearly see the lesion and the and even if it is low grade dysplasia in the repeated biopsies you should remove the lesion because the series vary but it it can go up to fifty percent of the cases where finally the the ultimate biopsy that you remove brings high grade dysplasure or even even more severe lesion. So visible lesion should be true should be removed regardless of the baseline biopsy.

Ian: Ian So visible lesion with low grade dysplasia that needs to be removed.

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah. Yeah.

Ian: Ian okay. But if it was not and it was a high quality exam, you and two pathologists agree it's low grade dysplasia and HP's been eradicated, follow them up in six to twelve months with a surveillance gastroscopy. Okay.

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah, yeah, yeah, yeah.

Ian: Ian What about so let's take it to the next step. What about high grade dysplasia? What do you do? It's approximately the same because of course, again, high quality endoscopy, nothing was seen. If it is high grade, the chances of the pathologies being, let's say, not correct, it's lower, then probably something visible is is occurring. That's the rationale to bring the patient earlier.

Ian: Ian Right.

Mario Dinis Ribeiro: Mario Dinis Ribeiro there are old studies coming, namely from the Netherlands where low grade dysplasia and high grade dysplasia were the main markers for progression because if you compare what we are describing in the stomach with what we described for several years in Barretts, it's the same, yeah. You need to go for low grade dysplasia detected consistently in two pathologists. It can happen in Barretts not that often in the stomach, in different places in the stomach. And then you should surveil more intensively. You do you do not propose to to ablate intestinal metaplasia in the stomach, that's the main difference. Or if you compare with also with ulcerative colitis, it was in the old times it was mostly a marker for colectomy. Nowadays we are more conservative with organ preservation, but it's it's the same rationale. We are moving away from random biopsies to target biopsies and we are moving away from only trusting pathologists to trust also our eyes and then to determine the risks.

Ian: Ian Okay, before I ask you about the resection, 'cause I assume you're gonna say if you're gonna resect something it should be using ESD, is that correct?

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah, I think we should in the stomach and in the upper GI because of the again, if you go to baseline risks, if you compare the alternatives it's surgical resection and you don't you want to avoid un unnecessary surgeries. This may be different from the colon, but I will not get into that discussion. But in the in the upper GI I think more and more we should go for unblocked resection. So if you have a very, very tiny lesion with eight to ten millimetres, and if you think you can do it unblock not by ESD. More and more the techniques are for us. For the patients and for the community, you should defend either piecemeal or unblock. And if the results are the same then it's probably easier to to go ahead with piecemeal. and we may bring different layers like less recurrence, less surveillance, a greener endoscopy. So but in in the end, yes, unblock and nowadays ESD.

Ian: Ian Okay, so let's say I'm gonna push you on this. You know, I don't have a Mario Dinis-Ribeiro who does gastric ESDs close to me. What about doing full thickness resection if it's less than twenty millimetres?

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah, it's it's possible. it's not the standard nowadays, I I would say in

Ian: Ian Correct.

Mario Dinis Ribeiro: Mario Dinis Ribeiro most modes most standards. So if you do have if E F T R it's kind of strange that you don't have anyone trained in EST because it's not in and eventually the stomach, it's not probably the organ that is more difficult if you of course if you do it in the fornix or in the upper GI in the upper stomach. But even the in the training curve conventionally you defend that antrum and in the incisura where most of these lesions will occur are not that difficult to be removed and blocked by ESD. I do think with all the referrals that we have been receiving, and I think this happens in Portugal, Spain, France, Romania, all over Europe at least, if you don't have it in your centre, you should refer that patient to the surroundings. So it's not about you, it's about the patient that needs to be treated. And you should not offer you shouldn't yeah, you should

Ian: Ian Okay, that's a that's a great recommendation. Okay.

Mario Dinis Ribeiro: Mario Dinis Ribeiro not offer surgery on one side or a suboptimal treatment just because you or nobody in your team can do it.

Ian: Ian Okay. Okay, good. I'm that's I like that answer a lot. Let me let me just go back for a second because I really didn't ask you about this. When you're doing surveillance or let's say you're doing the gastric mapping to look for multifocal intestinal metaplasia, I assume you're gonna say that we all should be using at a minimum high definition white light with the ability to use something like NBI or I scan or FICE. Do you agree with that?

Mario Dinis Ribeiro: Mario Dinis Ribeiro Yeah, so the technologies have been involved, they are ultimately the same between the providers. we have been publishing also manuscripts describing the features for NBI from Olympus or even for BLI and LCI from Fuji. However, I would say that if you are if you do use high definition scopes nowadays it's at the distance of a button. So it's so easy to turn on the virtual chromoendoscopy. The next step is to to know what you see. And again, if you are not that trained in in the stomach, but you come from the northern part of Europe and you are used to see Barretts, then it the pattern are similar. So you should look for something that it's a different color, it reminds you of a different causal pattern and of course if there are irregularities you should target the biopsies there. So yes, I would say that nowadays at least high resolution endoscopy and then introduce the layer of of virtual comendoscopy because it's said, at least with the new scopes, that it increased detection and you can then target the biopsies that you would do randomly and you remember before those those descriptions that I've made to do the biopsy away from the pylores and in also in the corpus and you you can do this not random, not because these processes I also said that are multifocal. So there is a chance even if you if you do it on one spot that the intestine metaplasia that you would let's say have been missing would be just three millimetres to the side. So why not to use a target biopsy scheme? And this is what is suggested in the guidelines.

Ian: Ian So let me as as we're sort of getting towards the end of our of our time here, unfortunately, I'm gonna ask you to give me one or two recommendations in MAPS III that are really a genuine shift from MAPS II. I think maybe you mentioned one regarding biopsies and the angularis, but can can you give us one or two new recommendations that are different that are a change from MAPS II?

Mario Dinis Ribeiro: Mario Dinis Ribeiro One is the the comprehensiveness because we tried we realized from MAPS one and two that other societies and other parts in the globe capture this in different guidelines and they were kind of consistent, but there was something missing telling the entire story. So we brought an entire chapter of on screening. and defending the concept of opportunistic screening, meaning whenever you are doing a gastroscopy, you should not miss cancer and you should not miss staging of a at-risk patient. This is the first. The second, what we have been discussing in this podcast, the comprehensiveness of endoscopy versus histology. So it's not enough to have one biopsy. you should trust your eyes. And finally, ESGE took this decision, of bringing the management of superficial lesions also to this guideline and introducing concepts on surveillance after ESD because we will have to have a major role on decreasing the level and intensity of surveillance of these patients that are more and more frequent. So I would refer to these three blocks.

Ian: Ian Okay. So I mean the MAPS III guideline is is very comprehensive and if if the listeners out there they've not read it, I really strongly recommend that they do. They can you can actually go to the ESGE website. The guidelines are there, they're open access. We'd love you to join the society, but even if you're not a member of the society, you can actually get the MAPS III guideline through the ESGE website and read it. I think it's extremely important for patient care. What's one practical change that you would recommend to the everyday endoscopist regarding the management of intestinal metaplasia if they were to see a patient like this in clinic today or tomorrow, Mario?

Mario Dinis Ribeiro: Mario Dinis Ribeiro See the entire stomach. Yeah. Don't miss a cancer and then focus on intestine metaplasia. And for that, again, see the entire stomach. Try to learn whatever you and however you can, and then don't overestimate the risk for these patients, but also don't miss a chance to identify those that merit surveillance.

Ian: Ian so number one, just at baseline is do a high quality upper endoscopy. Take your time. Yeah. I mean

Mario Dinis Ribeiro: Mario Dinis Ribeiro Definitely. Definitely.

Ian: Ian I I think we've sort of I wouldn't say disregarded gastroscopy, but I think we've been so focused on colonoscopy and we've done a great job. I think we need now to refocus on upper endoscopy and have that same clarity of how we approach those examinations because there are data to show that we do miss early cancers in the stomach.

Mario Dinis Ribeiro: Mario Dinis Ribeiro Definitely like it is consistent that most of these patients with these changes will not harbour a significant risk. There is consistency of some of these patients needs surveillance, like we are discussing for Barretts and we discuss for for adenomas in the colon. So we have been trying to more and more suggesting that the baseline endoscopy that you do it should be perfect. Because if you don't have anything at that baseline endoscopy, then probably you should not come again to the system. Of course, if you are asymptomatic, to repeat it. However, there are some individuals that for different reasons will merit surveillance. And I think that this is one of the messages that we try to convey is that there is an opportunity for prevention here.

Ian: Ian Listen, Mario, first of all I want to thank you for your time today. I think this is a great podcast and we've we've had a great discussion. But before I say goodbye, I think we all wanna know what do you do when you're not in the endoscopy suite or you're not being the the chair of medicine. I know you play sports.

Mario Dinis Ribeiro: Mario Dinis Ribeiro I used to play handball. And during the last years I've been playing tennis and paddle. I had an injury one year ago and I just now I run and I I go to to gyms. And I love to read. So I try to read very often and there are several types of books. crime or philosophy. I try always to have two or three in my reading list and and I love to travel with with family and friends and the the children are grown now so it's it's more difficult to to gather them but it's

Ian: Ian yeah.

Mario Dinis Ribeiro: Mario Dinis Ribeiro yeah, so it's

Ian: Ian I hear I that's it's almost impossible to get all the the adult kids together for a family trip, but we we still try as well. But listen, I want to thank you again, Mario. congratulations again on MAPS III. It's a great document. Again, I really think everybody should read it, download it, get to know it, and we'll wait for MAPS four down the road. And thanks again and have a great day, Mario.

Mario Dinis Ribeiro: Mario Dinis Ribeiro Thank you so much.

Ian Gralnek: Ian Gralnek Thank you for listening to this episode of Endoscopy Unplugged. If you found this podcast useful, please subscribe wherever you get your podcasts. And remember, they drop on the third Thursday of each month. To find out more about the European Society of Gastrointestinal Endoscopy, for example, to browse our scientific publications, visit our website at esge.com. And of course we'd love to hear your feedback. What would you like to hear more of? Send your thoughts to podcast at ESGE dot com. Thanks for listening and join us next time.